Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer

Ursula A. Matulonis, MD
Published: Monday, Mar 26, 2018


Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

The phase I/II trial, which enrolled 62 women, identified the recommended phase II dose of niraparib at 200 mg daily and pembrolizumab at 200 mg daily.

In women with platinum-resistant ovarian cancer who do not have a BRCA mutation, there was a 26% response rate. Matulonis notes that this result is noteworthy, as single-agent response rates with PARP inhibitors or immunotherapy agents in this patient population are under 10%. In women with platinum-resistant ovarian cancer who do have a BRCA mutation, there was a 29% response rate.

These results are very exciting, and Matulonis says she believes this combination should move forward into larger clinical testing.

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

The phase I/II trial, which enrolled 62 women, identified the recommended phase II dose of niraparib at 200 mg daily and pembrolizumab at 200 mg daily.

In women with platinum-resistant ovarian cancer who do not have a BRCA mutation, there was a 26% response rate. Matulonis notes that this result is noteworthy, as single-agent response rates with PARP inhibitors or immunotherapy agents in this patient population are under 10%. In women with platinum-resistant ovarian cancer who do have a BRCA mutation, there was a 29% response rate.

These results are very exciting, and Matulonis says she believes this combination should move forward into larger clinical testing.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Publication Bottom Border
Border Publication
x